ProMIS Neurosciences Announces Private Placement Financing

Rhea-AI Summary

ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has secured total financing of $9.2 million through multiple channels. This includes a $2.4 million private placement through warrant sales at $0.1875 per share, $6.8 million from existing warrant exercises, and $0.8 million from a registered offering.

The new warrants have an exercise price of $1.25 per share with a five-year expiration term. The private placement, expected to close on July 24, 2025, received support from an existing healthcare-focused institutional investor. Funds will support the clinical development of PMN310, the company's lead therapeutic candidate, and general corporate expenses.

Positive

• Secured significant total financing of $9.2 million to advance clinical development
• Strong investor confidence demonstrated by existing warrant exercises worth $6.8 million
• 5-year warrant term provides long-term funding flexibility
• Support from existing healthcare-focused institutional investor indicates continued confidence

Negative

• Dilutive impact from warrant issuance and potential future exercises
• Warrant exercise price of $1.25 represents potential future dilution if exercised
• Company relies on private placements for funding rather than traditional financing

News Market Reaction

-26.79%

35 alerts

-26.79% News Effect

-30.6% Trough in 24 hr 39 min

-$13M Valuation Impact

$37M Market Cap

0.6x Rel. Volume

On the day this news was published, PMN declined 26.79%, reflecting a significant negative market reaction. Argus tracked a trough of -30.6% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $37M at that time.

Data tracked by StockTitan Argus on the day of publication.

$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered offering for gross proceeds of $9.2 million

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced that it has entered into a purchase agreement (the “Purchase Agreement”) with an existing institutional and accredited investor to issue and sell an aggregate of approximately $2.4 million of warrants (the “Warrants”). The Warrants were sold at a price of $0.1875 per share through a private investment in public equity (“PIPE”) financing.

The Warrants have an exercise price of $1.25 per Warrant Share, are immediately exercisable and will expire five years from the date of initial issuance.

The PIPE financing included participation from an existing healthcare focused institutional investor.

ProMIS anticipates the gross proceeds from the PIPE financing to be approximately $2.4 million, before deducting fees and other offering expenses payable by the Company. In conjunction with the proceeds from the exercise of existing warrants, the total gross proceeds to the Company inclusive of the PIPE Offering will be approximately $9.2 million. The PIPE financing is expected to close on July 24, 2025, subject to customary closing conditions.

Proceeds from the PIPE financing are expected to be used to advance the clinical development of PMN310, ProMIS’ lead therapeutic candidate, as well as for working capital and other general corporate expenses.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (“Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. ProMIS Neurosciences has agreed to file a registration statement with the SEC registering the resale of the Common Shares issuable upon the exercise of the Warrants issued in the PIPE financing.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or other jurisdiction.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, predicts novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, ‎‎”forward-looking information”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the ‎use of forward-looking terminology such as “plans”, “excited to”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, ‎‎”is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and ‎phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be ‎achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or ‎circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the expected timing for the closing of the PIPE financing and the anticipated use of proceeds from the PIPE financing. Statements containing forward-looking information are not historical facts but instead represent management’s current ‎expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events ‎and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to ‎known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, ‎performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that clinical results or early results may not be indicative of future results, the Company’s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the “Risk Factors” section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. For further information:

Please submit media inquiries to info@promisneurosciences.com

For Investor Relations, please contact:
Kaytee Bock Zafereo
katherine.bock@promisneurosciences.com 

FAQ

How much funding did ProMIS Neurosciences (PMN) raise in the July 2025 financing?

ProMIS raised total gross proceeds of $9.2 million, comprising $2.4 million from warrant sales, $6.8 million from warrant exercises, and $0.8 million from a registered offering.

What are the terms of PMN's new warrants issued in July 2025?

The warrants were sold at $0.1875 per share, have an exercise price of $1.25, are immediately exercisable, and expire in five years.

How will ProMIS Neurosciences use the proceeds from the July 2025 financing?

The proceeds will be used to advance the clinical development of PMN310, their lead therapeutic candidate, and for working capital and general corporate expenses.

When will ProMIS Neurosciences' private placement close?

The private placement is expected to close on July 24, 2025, subject to customary closing conditions.

What diseases does ProMIS Neurosciences (PMN) target?

ProMIS focuses on developing therapeutic antibodies for neurodegenerative diseases, including Alzheimer's disease, ALS (amyotrophic lateral sclerosis), and Parkinson's disease.